Gene

TET2

tet methylcytosine dioxygenase 2

Explore in graph →CI-GENE-00034922HGNC:25941 ENSG00000168769 NCBI 54790 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (8)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AXIN2 P455K + BAX L76R + BRAF V600E + CDKN2A Deletion + CDKN2B Deletion + TET2 E796KCDKN2B TET2 BAX AXIN2 BRAF CDKN2A1

Cohorts

Alteration frequency by cohort (156)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved156 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Rectal Cancer (MSK, Nature Medicine 2022) rectal_msk_2022	unmapped	Ssm	18	788

Literature

Linked publications (4)

25 per page, newest first.

pubmedPublishedShowing 1–4 of 4 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
· J Clin Oncol · 2012 · PMID 22430270 · validated civic_curation pubmed
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
· Blood · 2009 · PMID 19666869 · validated civic_curation pubmed
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
· J Clin Oncol · 2011 · PMID 21343549 · validated civic_curation pubmed
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
· Blood · 2011 · PMID 21828143 · validated

TET2 Mutation7
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support N/A	4	accepted	EID415 In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death… (full text at CIViC) PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC	civic
〃	Myelodysplastic SyndromeCURATED_BROADER	Prognostic	B	Supports Better Outcome	4	accepted	EID417 In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations. PMID 19666869 · Kosmider et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Better Outcome	4	accepted	EID419 In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission. PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports N/A	4	accepted	EID421 In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete r… (full text at CIViC) PMID 21343549 · Metzeler et al., 2011 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID426 In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis. PMID 21828143 · Chou et al., 2011 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID427 In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorte… (full text at CIViC) PMID 21343549 · Metzeler et al., 2011 · Open in CIViC	civic
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11992 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic

TET2 Mutation7

(prognostic)

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Does Not Support N/A

accepted

EID415

In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death… (full text at CIViC)

PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC

civic

〃

Myelodysplastic SyndromeCURATED_BROADER

Prognostic

Supports Better Outcome

accepted

EID417

In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.

PMID 19666869 · Kosmider et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Better Outcome

accepted

EID419

In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.

PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports N/A

accepted

EID421

In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete r… (full text at CIViC)

PMID 21343549 · Metzeler et al., 2011 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID426

In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.

PMID 21828143 · Chou et al., 2011 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID427

In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorte… (full text at CIViC)

PMID 21343549 · Metzeler et al., 2011 · Open in CIViC

civic

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11992

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

civic